A Multi-center Prospective Study of Branch Atheromatous Disease in China
A Multi-center Prospective Study of Branch Atheromatous Disease in China
Branch atheromatous disease (BAD), is regarded as one of the important etiologies for acute isolated subcortical infarction, especially in Asian population. However, due to the fact that the existing imaging techniques cannot depict small vessel changes, the clinical diagnosis, therapy and research of BAD are facing challenges. We have started a multi-center prospective observational study of BAD in China, aiming at establishing a large-sample clinical-radiological cohort of BAD, analyzing predictors for functional outcome, and exploring the efficacy of tirofiban on BAD. A standardized Case Report Form (and eCRF on website) is used to collect baseline and follow-up information on epidemiological, clinical, radiological(MRI, SWI, MRA, HRMRI,3TVWI)and blood test. The primary outcome was mRS on 90 days with blind evaluation.
Inclusion Criteria:
3) No ≥50% stenosis on the parent artery of the criminal vessel (i.e. corresponding basilar or middle cerebral artery) (confirmed by MRA or CTA or DSA).
5.Signed informed consent by the patient or legally authorised representatives
Exclusion Criteria:
lishengde.medicine@qq.com17896002828
pumchnijun@163.com8601069154059